PHILADELPHIA, July 07, 2026 (GLOBE NEWSWIRE) —
ADMA BIOLOGICS, INC. (NASDAQ: ADMA):
Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) breached their fiduciary duties to the company and its shareholders.
What Is This Investigation About? Grabar Law Office is investigating allegations that ADMA’s officers and directors failed to implement and maintain adequate internal controls and oversight mechanisms concerning the Company’s revenue recognition practices, related-party transactions, and public disclosures.
If you purchased ADMA Biologics (NASDAQ: ADMA) shares prior to August 9, 2024, and still hold shares today, you
can
seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost or fee to you whatsoever – ever. Visit
https://grabarlaw.com/the-latest/adma-shareholder-investigation/
, email Joshua H. Grabar at
[email protected]
, or call us at 267-507-6085.
What Is Alleged? According to recently filed securities fraud class action, ADMA allegedly:
- Failed to disclose certain related-party transactions involving entities allegedly associated with Company insiders;
- Engaged in practices that allegedly inflated reported revenue through channel-stuffing activities;
- Maintained inadequate internal accounting and disclosure controls;
- Made materially misleading statements concerning the effectiveness of internal controls and financial reporting;
- Failed to provide shareholders with accurate information concerning the Company’s business operations, revenues, and prospects; and
- Exposed the Company to significant legal, regulatory, reputational, and financial risk.
On March 24, 2026, a research report publicly challenged ADMA’s reported growth and alleged that the Company had engaged in channel-stuffing practices and failed to disclose a material related-party distribution relationship. The report further alleged that ADMA’s reported revenue growth was materially overstated and that substantial product inventory had accumulated within distribution channels.
What Can You Do Now?
If you purchased ADMA Biologics (NASDAQ: ADMA) shares prior to August 9, 2024, and still hold shares today, please visit
https://grabarlaw.com/the-latest/adma-shareholder-investigation/
, email Joshua H. Grabar at
[email protected]
, or call us at 267-507-6085. You
can
seek
claims on behalf of the Company against officers and directors responsible for alleged corporate wrongdoing, corporate governance reforms designed to protect the Company and its shareholders,
and a court approved incentive award at no cost or fee to you whatsoever – ever. #ADMA $ADMA #ADMABiologics
GENEDX HOLDINGS CORP. (NASDAQ: WGS):
Grabar Law Office is investigating claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS).
WHAT IS THIS INVESTIGATION ABOUT? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased
GeneDx Holdings Corp. (NASDAQ: WGS)
shares prior to April 16, 2025
,
and still hold shares today,
you are encouraged to visit
https://grabarlaw.com/the-latest/genedx-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
WHY? As alleged in a recently filed securities fraud class action complaint, GeneDx Holdings Corp. (NASDAQ: WGS), through certain of its executives, violated federal securities laws by making false and/or misleading statements pertaining to the impact of the Fabric acquisition on the overall business of the Company. It is alleged that WGS repeatedly made statements that would have caused the average investor to believe that the Fabric acquisition would improve the Company’s financials and create efficiencies between it and the Company’s core business. These include statements such as: “There is room to run in terms of reducing COGS in the future by combining the best of capability between GeneDx and Fabric as we lean into the best possible algorithms to optimize dry lab processes.” These and similar statements when made were false. In truth, it is alleged, Defendants knew of, or recklessly disregarded, significant problems in Fabric’s viability that would negatively impact WGS’s overall business and operations. As a result, the Company’s statements concerning its business, operations, and prospects lacked a reasonable factual basis.
WHAT CAN YOU DO NOW?
If you purchased
GeneDx Holdings Corp. (NASDAQ: WGS)
shares prior to April 16, 2025
,
and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit
https://grabarlaw.com/the-latest/genedx-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085. $WGS #WGS #GeneDX
NAVAN, INC. (NASDAQ: NAVN):
Grabar Law Office is investigating whether certain officers and directors of Navan, Inc. (NASDAQ: NAVN) breached their fiduciary duties owed to the Company and its shareholders.
WHAT IS THIS INVESTIGATION ABOUT? Grabar Law Office is investigating allegations concerning Navan’s disclosures, internal reporting systems, oversight practices, and public statements made in connection with the Company’s October 30, 2025 initial public offering (“IPO”).
If you are a current Navan Inc. (NASDAQ: NAVN) shareholder who has continuously held Navan shares since on or shortly after the Company’s October 30, 2025 IPO, you are encouraged to visit
https://grabarlaw.com/the-latest/navan-shareholder-investigation/
, contact Joshua H. Grabar at
[email protected]
, or call us at 267-507-6085 to discuss your rights and potential claims. You can pursue claims on behalf of Navan against officers and directors responsible for alleged misconduct and seek corporate governance reforms designed to improve oversight, transparency, disclosure practices, and shareholder value, including a court approved service award at no cost to you whatsoever.
WHY? As alleged in a federal securities fraud class action complaint, Navan, Inc. (NASDAQ: NAVN) represented in its IPO materials that it had experienced significant growth in revenue, gross booking volume (“GBV”), and platform adoption. The Company’s offering documents highlighted strong historical growth metrics and discussed plans to continue expanding customer relationships and platform usage. Navan’s October 30, 2025, IPO offering documents allegedly omitted material information concerning the Company’s business and financial condition, including that at the time of the IPO, Navan possessed information indicating that revenue growth was decelerating and that the Company would substantially increase sales and marketing spending in order to sustain reported growth metrics. The complaint further alleges that these trends were not adequately disclosed to investors in the Company’s registration statement and prospectus.
The investigation is focused on whether Navan’s directors and senior officers: (1) Failed to maintain adequate oversight concerning the Company’s growth trends and operating performance; (2) Failed to ensure that material information concerning revenue trends and operating expenses was timely escalated and disclosed; (3) Failed to maintain effective disclosure controls and procedures; (4) Caused or permitted the dissemination of allegedly misleading registration statement and prospectus disclosures; (5) Failed to provide shareholders with complete information regarding the Company’s sales and marketing expenditures and their impact on future performance; and (6) Exposed the Company to significant legal, financial, and reputational harm.
WHAT CAN YOU DO NOW?
If you are a current Navan Inc. (NASDAQ: NAVN) shareholder who has continuously held Navan shares since on or shortly after the Company’s October 30, 2025 IPO, you are encouraged to visit
https://grabarlaw.com/the-latest/navan-shareholder-investigation/
, contact Joshua H. Grabar at
[email protected]
, or call us at 267-507-6085. You can pursue claims on behalf of Navan against officers and directors responsible for alleged misconduct, seek corporate governance reforms designed to improve oversight, transparency, disclosure practices, and shareholder value, and a court approved service award at no cost to you whatsoever. #Navan #NAVN $NAVN
NEW ERA ENERGY & DIGITAL, INC. (NASDAQ: NUAI)
:
Grabar Law Office is investigating claims on behalf of shareholders of New Era Energy & Digital, Inc. (NASDAQ: NUAI) (formerly known as New Era Helium (NASDAQ: NEHC)).
WHAT IS THIS IVESTIGATION ABOUT?
The investigation concerns whether New Era and certain of its officers and directors breached their fiduciary duties owed to the Company.
If you purchased New Era Energy & Digital, Inc. (NASDAQ: NUAI) shares (formerly
known as New Era Helium (NASDAQ: NEHC)),
on or shortly after the Company’s December 9, 2024 IPO, and continue to hold shares today, please visit
https://grabarlaw.com/the-latest/newera-shareholder-investigation-2/
c
ontact Joshua H. Grabar at
[email protected]
,
or call 267-507-6085. You may be able to seek corporate governance reforms, the return of funds back to the Company, and a court-approved incentive award at no cost to you whatsoever.
WHY?
According to a recently filed federal securities fraud class action complaint, New Era Energy & Digital, Inc. (NASDAQ: NUAI), through certain of its officers, allegedly made false and misleading statements concerning the Company’s Texas Critical Data Centers project, permitting progress, environmental liabilities, and related-party oil and gas transactions. The complaint alleges that New Era overstated its progress in obtaining regulatory permits and advancing its purported flagship Texas Critical Data Centers project, while publicly touting “tangible progress across all fronts including engineering, permitting, regulatory filings, and land expansion.” According to the complaint, the Company also represented to investors that it was making substantial progress toward a large-scale AI and high-performance computing data center campus in West Texas. It is alleged that that New Era’s AI pivot was largely a “fantasy,” and that despite Company representations regarding permitting progress, “no applications have even been submitted” for required construction and environmental permits. It is further alleged that a substantial number of New Era’s gas wells had been acquired from bankrupt entities tied to Company insiders and accused management of engaging in financial practices designed to enrich insiders while avoiding environmental cleanup obligations.
On December 29, 2025, reports emerged that the New Mexico Attorney General had filed suit against New Era, its subsidiary Solis Partners, LLC, and Company CEO Everett Willard Gray II, alleging a “fraudulent oil-and-gas scheme” involving self-dealing transactions, shell entities, and strategic bankruptcies designed to evade plugging and remediation obligations for inactive wells. According to that complaint, the alleged scheme involved transferring wells among affiliated entities while leaving environmental liabilities behind in bankruptcy proceedings.
WHAT CAN YOU DO NOW
? If you purchased or otherwise acquired New Era Energy & Digital, Inc. (NASDAQ: NUAI) shares (formerly known as New Era Helium (NASDAQ: NEHC)), on or shortly after its December 9, 2024 IPO, and continue to hold shares today, you can seek corporate governance reforms, the return of funds back to the Company, and a court-approved incentive award at no cost to you whatsoever. Visit
https://grabarlaw.com/the-latest/newera-shareholder-investigation-2/
,
email Joshua Grabar at
[email protected]
,
or call us at 267-507-6085.
#NewEraEnergy #NUAI $NUAI #NewEnergyHelium #NEHC $NEHC
About Grabar Law Office
:
Grabar Law Office represents institutional and individual investors in shareholder derivative litigation, securities litigation, corporate governance matters, and antitrust litigation nationwide. The firm has extensive experience prosecuting claims involving breaches of fiduciary duty, failures of oversight, misleading disclosures, inadequate internal controls, and corporate governance failures.
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: [email protected]
